The congress will highlight competition in anti-CD20 and other novel multiple sclerosis drug classes
Of all the new products helping Roche transition away from its old blockbuster portfolio, multiple sclerosis drug Ocrevus (ocrelizumab) is one of the biggest contributors.
Now other companies with similar products in development are trying to get in on the act, and data for these...
The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.
The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.
The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.
Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.
Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.
The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.
Lynkuet will compete with Astellas's Veozah/Veoza
